Illumina Launches Pilot Proteomics Program with UK Biobank and Industry Partners

NavDx Test Expands Availability for Enhanced Surveillance in HPV+ Anal Cancer Patients

QIAGEN Enhances QIAcuity Digital PCR with Expanded Multiplexing Capabilities

Boehringer Ingelheim Licenses Synaffix’s ADC Technology to Advance Cancer Therapies

AIG Hospitals to Launch ₹800 Crore Oncology Centre with South-East Asia’s First Dynamic ARC Proton Therapy

Qiagen Secures FDA Clearance for QIAstat-Dx Gastrointestinal Panel

Ovation.io Launches Groundbreaking GLP-1 Research Dataset to Advance Precision Medicine

Kotak Invests ₹940 Crore in Neuberg Diagnostics to Drive Expansion and IPO Preparation

NICE Recommends Olaparib for BRCA-Mutated Advanced Breast Cancer

SOPHiA GENETICS and Platomics Collaborate to Streamline IVDR Compliance for Clinical Labs

India Unveils Genome Sequencing Data of 10,000 Individuals: A Milestone in Biotechnology Research

Ambry Genetics Advances BRCA2 Variant Classification with CRISPR-Based Study Published in *Nature*

Geneoscopy Secures $105M Series C Funding to Advance Colorectal Cancer Screening

Vertex and Orna Partner to Develop In Vivo Gene Therapies for Blood Disorders

FDA Grants Priority Review to Dizal’s Sunvozertinib for EGFR Exon20ins NSCLC

Home
/
update
/
details

QIAGEN Enhances QIAcuity Digital PCR with Expanded Multiplexing Capabilities

NextEdge Admin

13 Jan 2025

2 min 14 sec

QIAGEN has significantly enhanced its QIAcuity Digital PCR (dPCR) system, doubling its multiplexing capacity from five to 12 targets per sample. This upgrade, achieved through a software update and the launch of the QIAcuity High Multiplex Probe PCR Kit, expands applications in translational research, microbiome analysis, pathogen detection, and cell and gene therapy development.

The new capabilities allow researchers to analyze more targets simultaneously without hardware changes, optimizing sample use while reducing time and reagent consumption. The QIAcuity High Multiplex Probe PCR Kit includes a ready-to-use master mix designed for microfluidic use in QIAcuity Nanoplates, enhancing probe-based dPCR specificity and efficiency. The required QIAcuity Software 3.1 introduces crosstalk compensation, ensuring accurate multi-target analysis.

QIAcuity’s adoption has been strong, with over 2,700 placements by the end of 2024 and more than 550 scientific citations. The platform serves pharmaceutical and biotech companies, research institutions, and forensic labs. In late 2024, QIAGEN expanded into clinical testing with the QIAcuityDx system.

QIAcuity’s high-throughput, automation-friendly dPCR technology partitions samples into thousands of microreactions, enabling precise DNA and RNA quantification. Its integrated workflow—combining partitioning, thermocycling, and imaging—reduces processing time from six hours to just two. Available in one-, four-, and eight-plate versions, QIAcuity meets diverse laboratory needs.

With this upgrade, QIAcuity strengthens its position as a leading dPCR solution, providing researchers with deeper biological insights in a cost-efficient manner.